Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7159712 | 0.93 | CYP4F2 (0.64) | CYP4F2CYP4A11F2RL1CYP4Z1KMT2A | |
| SCHEMBL12290429 | 0.89 | CYP4F2 (0.58) | CYP4F2CYP4A11F2RL1CYP4Z1ALOX5 | |
| SCHEMBL304455 | 0.86 | CYP4F2 (0.74) | CYP4F2CYP4A11CYP4Z1KMT2ACA12 | |
| SCHEMBL3678807 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11F2RL1CYP4Z1KMT2A | |
| SCHEMBL5641153 | 0.86 | CYP4F2 (0.55) | CYP4F2CYP4A11F2RL1CYP4Z1KMT2A | |
| SCHEMBL717900 | 0.85 | TDP1 (0.56) | CYP4F2CYP4A11HDAC2HDAC8ALOX5 | |
| Ethane SCHEMBL27846059 | 0.85 | CYP4F2 (0.72) | CYP4F2CYP4A11CYP4Z1KMT2ACA12 | |
| SCHEMBL10763604 | 0.84 | F2RL1 (0.73) | CYP4F2CYP4A11F2RL1KMT2AALOX5 | |
| SCHEMBL6400651 | 0.84 | F2RL1 (0.47) | CYP4F2CYP4A11F2RL1CYP4Z1TRPV1 | |
| SCHEMBL4077327 | 0.83 | KMT2A (0.49) | CYP4F2CYP4A11CYP4Z1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101868463-B | Novel polyspirocyclic compounds, their use in the treatment of malaria or toxoplasmosis and processes for their preparation | UNIV JOSEPH FOURIER | 2013-05-01 | — | — | CN | disclosed |
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| US-8389569-B2 | Polyspirane compounds, application thereof in the treatment of malaria or toxoplasmosis and method for preparing same | UNIVERSITE JOSEPH FOURIER (FR) | 2013-03-05 | — | — | US | disclosed |
| EP-2195323-B1 | Polyspirane compounds, use thereof in the treatment of malaria or toxoplasmosis and method for their preparation | UNIV JOSEPH FOURIER (FR) | 2011-12-28 | — | — | EP | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2010-11-25 | — | — | US | disclosed |
| CN-101868463-A | Novel polyspirocyclic compounds, their use in the treatment of malaria or toxoplasmosis and processes for their preparation | UNIV JOSEPH FOURIER | 2010-10-20 | — | — | CN | disclosed |
| WO-2009077677-A2 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | UNIVERSITE JOSEPH FOURIER (FR) | 2009-06-25 | — | — | WO | disclosed |
| US-6348618-B1 | PREPARING ORGANOLEPTIC OR ANTIMICROBIAL COMPOUNDS BY CONTACTING BETA-KETO ESTER WITH MATERIAL SELECTED FROM BACTERIA, ENZYMES, AND MATERIAL HAVING ACIDIC OR ALKALINE PH, ELEVATING TEMPERATURE, EXPOSING TO LIGHT | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2002-02-19 | — | — | US | disclosed |
| US-6222062-B1 | USEFUL AS PRECURSORS FOR ORGANOLEPTIC COMPOUNDS, ESPECIALLY FOR FLAVORS, FRAGRANCES AND MASKING AGENTS AND ANTIMICROBIAL COMPOUNDS | GIVAUDAN ROURE (INTERNATIONAL) SA (CH) | 2001-04-24 | — | — | US | disclosed |
| EP-1090624-A2 | Beta ketoester | Givaudan SA (CH) | 2001-04-11 | — | — | EP | disclosed |
| EP-0911315-A1 | Beta-ketoester | Givaudan Roure (International) S.A. (CH) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298422-A1 | NOVEL POLYSPIRANE COMPOUNDS, APPLICATION THEREOF IN THE TREATMENT OF MALARIA OR TOXOPLASMOSIS AND METHOD FOR PREPARING SAME | FLOT1, PHOSPHO1, GPAA1 | CYP4F2 2062/4885CYP4A11 1772/4885F2RL1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.